MoonLake Immunotherapeuti...

NASDAQ: MLTX · Real-Time Price · USD
54.02
-0.86 (-1.57%)
At close: Aug 15, 2025, 12:40 PM

Company Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.

It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation.

The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.

MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics
MoonLake Immunotherapeutics logo
Country CH
IPO Date Oct 20, 2020
Industry Biotechnology
Sector Healthcare
Employees 100
CEO Jorge Santos da Silva

Contact Details

Address:
Dorfstrasse 29
Zug,
CH
Website https://www.moonlaketx.com

Stock Details

Ticker Symbol MLTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001821586
CUSIP Number 61559X104
ISIN Number KY61559X1045
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Jorge Santos da Silva Ph.D. Co-Founder, Chief Executive Officer & Director
Matthias Bodenstedt Chief Financial Officer
Carla Bretes Director of Investor Relations & External Communications
Dr. Kristian Reich M.D., Ph.D. Co-Founder & Chief Scientific Officer
Joana Cortez Senior Director Legal & Compliance
Luciana Marques Director of HR, People & Culture
Nicolas Mosimann Ph.D. General Counsel
Nuala Brennan Chief Clinical Development Officer
Oliver Daltrop Ph.D. Chief Operations Officer
Tino Anthamatten Vice President of Marketing, Market Access & Pricing

Latest SEC Filings

Date Type Title
Aug 14, 2025 SCHEDULE 13G Filing
Aug 06, 2025 SCHEDULE 13G/A [Amend] Filing
Aug 05, 2025 10-Q Quarterly Report
Aug 05, 2025 8-K Current Report
Jul 07, 2025 4 Filing
Jun 09, 2025 4 Filing
Jun 09, 2025 4 Filing
Jun 09, 2025 4 Filing
Jun 09, 2025 4 Filing
Jun 09, 2025 4 Filing